Translation Acceleration Grants in Predictive Markers 2018
Prostate Cancer Canada is pleased to announce the successful applications from the recent Movember Translation Acceleration Grants competition. Prostate Cancer Canada (PCC) solicited proposals from groups developing and validating methods that can help clinicians determine the most effective treatment for their patients. The end goal is the clinical validation of the approach to improve decision making in the management of prostate cancer.
| Principal Investigator |
Institution |
Title |
Funding |
| Tarek Bismar |
University of Calgary |
Characterization of novel molecular signature for accurately predicting prostate cancer progression in active surveillance |
$959,999 |
| Kim Chi |
BC Cancer |
Clinical Utility of cfDNA for Prognostic and Predictive Biomarkers for Advanced Prostate Cancer |
$1,500,000 |
| Housheng He |
University Health Network |
Combination of subpathology and noncoding RNA: integrating outcome prediction and treatment individualization for intermediate-risk prostate cancer |
$1,499,250 |
Movember Translation Acceleration Grants 2018
| Principal Investigator |
Institution |
Title |
Funded Amount |
| Francois Benard |
BC Cancer Agency – Vancouver, BC |
National Program on Radioligand Therapy for Prostate Cancer |
$4,500,000 |
| Funded starting January 1, 2018 for 5 years Total: |
$4,500,000 |
| Team Members: |
Institutions: |
Jean-Mathieu Beauregard
Co-Principal Investigator |
Université Laval
Quebec, QC |
Kim Chi
Co-Principal Investigator |
BC Cancer Agency
Vancouver, BC |
Wanrudee Isaranuwatchai
Co-Principal Investigator |
St Michael’s Hospital
Toronto, ON |
Stuart Peacock
Co-Principal Investigator |
University of British Columbia
Vancouver, BC |
Fred Saad
Co-Principal Investigator |
Centre de recherche du Centre hospitalier de l'Université de Montreal
Montreal, QC |
John Valliant
Co-Principal Investigator |
McMaster University
Hamilton, ON |
Katherine Zukotynski
Co-Principal Investigator |
McMaster University
Hamilton, ON |
Frederic Arsenault
Co-Investigator |
Centre de recherche du Centre hospitalier de l'Université de Montreal
Montreal, QC |
Glenn Bauman
Co-Investigator |
London Regional Cancer Centre
London, ON |
Alejandro Berlin
Co-Investigator |
University Health Network
Toronto, ON |
Kelvin Chan
Co-Investigator |
Sunnybrook Research Institute
Toronto, ON |
Neil Fleshner
Co-Investigator |
University Health Network
Toronto, ON |
Ur Metser
Co-Investigator |
University Health Network
Toronto, ON |
Frederic Pouliot
Co-Investigator |
Université Laval
Quebec, QC |
Dean Regier
Co-Investigator |
BC Cancer Agency
Vancouver, BC |
Patrick Veit-Haibach
Co-Investigator |
University Health Network
Toronto, ON |
Discovery Grants 2017
| Movember Discovery Grants |
| Principal Investigator |
Institution |
Project Title |
Funded Amount |
| Alison Allan |
University of Western Ontario |
Dynamic influence of the epithelial-to-mesenchymal transition on circulating tumor cell (CTC) generation, phenotype, and disease progression in prostate cancer |
$199,282 |
| Richard Austin |
McMaster University |
Disrupting the interaction of anti-GRP78 autoantibodies to tumour cell surface GRP78 as novel therapeutic approach for the treatment of prostate cancer |
$193,700 |
| Lori Brotto |
University of British Columbia |
Innovations in the treatment of sexual dysfunction and couple intimacy after prostate cancer: A randomized trial of mindfulness versus cognitive behavioural therapy |
$187,256 |
| Neil Fleshner |
University Health Network |
Assessing Positive Margins at Radical Prostatectomy Using Real-Time High Resolution Prostate-Specific Membrane Antigen-Based Gamma Imaging of the Prostate Bed |
$192,482 |
| Stanley Liu |
Sunnybrook Research Institute |
Interrogating radioresistance in prostate cancer: leveraging combined genomic and proteomic analyses |
$200,000 |
| Christopher Mueller |
Queen's University |
Markers of poor outcome in castrate resistant prostate cancer |
$200,000 |
| Caroline Pukall |
Queen's University |
Healthcare experiences and health-related quality of life in LGBTQ+ individuals with localized prostate cancer: A longitudinal, mixed-methods study with a special focus on psychosexual outcomes |
$199,583 |
| John Ronald |
Robarts Research Institute |
Tumour-Activatable Minicircles: Novel Transcription-Based Blood/Urine Assays for Assessing Prostate Cancer Aggressiveness |
$200,000 |
| Greg Stanisz |
Sunnybrook Research Institute |
Chemical Exchange Saturation Transfer MRI as a Biomarker of Tumour Response to Radiation Treatment |
$199,999 |
| Jose Teodoro |
McGill University |
The vaculoar ATPase complex as a therapeutic target in prostate cancer |
$200,000 |
| Theodorus van der Kwast |
University Health Network |
Molecular-genetic characterization of a cancer field effect associated with intraductal carcinoma of the prostate |
$200,000 |
| Alexander Wyatt |
University of British Columbia |
Genomic truncation of the Androgen Receptor in poor-prognosis castration-resistant prostate cancer |
$200,000 |
| Funded starting July 1, 2017 for 2 years Total: |
$2,372,302 |
| PCC Discovery Grants |
| Principal Investigator |
Institution |
Project Title |
Funded Amount |
| Linganatha Adisesh |
University of New Brunswick |
Cadmium, Arsenic and other metal exposures as determinants of prostate cancer in the Canadian Atlantic provinces |
$152,020 |
| Kerry Courneya |
University of Alberta |
Exercise during Active Surveillance for Prostate Cancer: The ERASE Trial |
$76,000 |
| Tsz Kin (Bernard) Lee |
BC Cancer Agency - Fraser Valley |
The Comprehensive Prostate Cancer Assessment on Sexual Health for Men-Who-Have-Sex-with-Men (COMPASS) |
$44,370 |
| Funded starting July 1, 2017 for 2 years Total: |
$272,370 |
PCC NextGen Awards 2017
| Type |
Principal Investigator |
Institution |
Title |
Award Amount |
| Clinical Research Fellowship to Steven Yip |
Kim Chi |
BC Cancer Agency - Vancouver |
The Germline Genetics of Prostate Cancer (GENPRO): Caring for Patients with Hereditary Prostate Cancer and their Families |
$75,000 |
| Philip Feldberg Graduate Studentship to Lavinia Carabet |
Artem Cherkasov |
University of British Columbia |
Computer-aided discovery of small molecule inhibitors targeting the MYC-MAX complex as prospective therapeutics for castration-resistant prostate cancer |
$75,000 |
| Graduate Studentship to Douglas Brown |
John Lewis |
University of Alberta |
Suicide gene therapy to destroy prostate cancer |
$75,000 |
| Post-Doctoral Research Fellowship to Fanny Gaignier |
Yves Fradet |
Université Laval |
Development of a new approach for prostate cancer immunotherapy |
$105,000 |
| Funded starting from July 1, 2017 for 1 or 2 years Total: |
$330,00 |
Translation Acceleration Grants 2017
| Movember Translation Acceleration Grants |
| Principal Investigator |
Institution |
Title |
Funded Amount |
| Sylvain Martel |
Polytechnique Montreal |
Translational procedures and interventional platforms for optimal delivery of therapeutics to prostate cancer based on magneto-aerotactic MC-1 agents |
$1,488,000 |
| Amina Zoubeidi |
University of British Columbia |
Targeting Neuroendocrine prostate cancer |
$1,495,665 |
| Funded starting April 1, 2017 Total: |
$2,983,665 |
| PCC Translation Acceleration Grant |
| Principal Investigator |
Institution |
Title |
Funded Amount |
| Alexandre Zlotta |
Sinai Health Systems |
Germline Mutations in the Kallikrein 6 and DNA repair genes including BRCA1/2 and Predisposition for Aggressive Prostate Cancer |
$1,455,778 |
| Funded starting April 1, 2017 Total: |
$1,455,778 |
PCC Request For Proposals in Prevention 2016
| Principal Investigator |
Institution |
Title |
Funded Amount |
| Carla Prado |
University of Alberta |
Targeted RFP in Prostate Cancer Prevention Evidence-based systematic review of modifiable risk factors for prostate cancer |
$24,367 |
| Funded starting July 25, 2016 for 7 months Total: |
$24,367 |
Movember Discovery Grants 2016
October 31, 2016 - Prostate Cancer Canada and Movember are proud to announce the successful recipients of the 2016 Movember Discovery Grants competition. The main goal of this program is to support researchers in that key stage of obtaining early results. The program supports both junior investigators early in their career and more established investigators to pursue new important directions. Applications are accepted from all areas of prostate cancer research. The goal is to support researchers to generate preliminary data in prostate cancer research that would provide the basis for a more substantial research grant in the future. The applications are evaluated by a rigorous peer-review process that assesses innovation, the track record of investigator and team, the feasibility of the proposed work and the potential impact on prostate cancer.
This represents an investment of $2,270,968 over 2 years starting July 1, 2016.
| Principal Investigator |
Institution |
Title |
Funded Amount |
| Richard Baverstock |
University of Calgary
Calgary, AB |
Measuring the relationship between overactive bladder symptoms and prostate cancer treatment: is it bi-directional? |
$186,904 |
| Vincent Fradet |
Université Laval
Quebec, QC |
Role of gut microbiota on anti-inflammatory effect of Omega-3 in prostate cancer |
$197,944 |
| Roseline Godbout |
University of Alberta
Edmonton, AB |
Role of a novel fatty acid binding protein (FABP12) in prostate cancer lipid metabolism and progression |
$199,820 |
| Housheng He |
University Health Network
Toronto, ON |
Identifying functional long noncoding RNAs in prostate cancer |
$198,000 |
| Madhuri Koti |
Queen's University
Kingston, ON |
PTEN regulated interferon pathways as novel therapeutic targets in prostate cancer |
$198,000 |
| Shawn Li |
Western University
London, ON |
Global and quantitative kinomic and phosphoproteomic analysis of advanced prostate cancer to enable effective treatment |
$200,000 |
| Hongshen Ma |
University of British Columbia
Vancouver, BC |
Investigating castrate resistant prostate cancer through transcriptome profiling of single CTCs |
$200,000 |
| Septimu Salcudean |
University of British Columbia
Vancouver, BC |
Quantitative multimodal imaging of prostate cancer |
$184,108 |
| Paul Toren |
Université Laval
Quebec, QC |
The role of serum steroids in the development of castrate resistant prostate cancer: a secondary analysis of the PR.7 trial |
$115,192 |
| Yuzhuo Wang |
University of British Columbia
Vancouver, BC |
Identification of potential therapeutic targets for AR pathway inhibitor-resistant prostate cancer |
$200,000 |
| Jian Hui Wu |
Lady Davis Institute for Medical Research
Montreal, QC |
Development of novel GATA2 inhibitors for breaking the critical AR-GATA2 feedback loop in castration-resistant prostate cancer |
$191,000 |
| Frank Wuest |
University of Alberta
Edmonton, AB |
Silicon-fluorine-PSMA: a winning team for early prostate cancer detection |
$200,000 |
Personnel Awards in Prostate Cancer Research 2016
October 25, 2016 - Prostate Cancer Canada is proud to announce the recipients of the 2016 Personnel Awards in Prostate Cancer Research. These awards are available to outstanding doctoral students, post- doctoral fellows and clinical research fellows studying prostate cancer. They provide recognition and funding early in academic research careers with an opportunity to continue training in an outstanding research environment.
This represents an investment of $495,000 over 2 years starting July 1, 2016.
| Award |
Awardee |
Institution |
Title |
Award Amount |
| Great Gulf Post-Doctoral Research Fellowship |
Jennifer Bossio |
University of British Columbia
Vancouver, BC |
Advances in the treatment of sexual dysfunction for men following prostate cancer: Applications for mindfulness-based cognitive therapy (MBCT) |
$105,000 |
| Ellis Don Post-Doctoral Research Fellowship |
Lindsay Hedden |
University of British Columbia
Vancouver, BC |
Evidence-informed decision making in cancer survivorship: evaluating a comprehensive, multi-disciplinary prostate cancer supportive care program |
$105,000 |
| Paul Flumian Post-Doctoral Research Fellowship |
Ravi Shashi Nayana Munuganti |
University of British Columbia
Vancouver, BC |
Development of Neural Transcription Factor BRN2 Inhibitors as Potential Therapeutics for Neuroendocrine Prostate Cancer |
$105,000 |
| Stewart McInnes Post-Doctoral Research Fellowship |
Guy Nir |
University of British Columbia
Vancouver, BC |
Radiomic Profiling Based on Digital Pathology for Improving Patient Stratification in Prostate Cancer Management |
$105,000 |
| Philip Feldberg Graduate Studentship |
Natalie Fox |
University of Toronto/ Ontario Institute for Cancer Research
Toronto, ON |
Characterization and clinical consequences of genome-transcriptome associations in intermediate risk prostate cancer |
$75,000 |
Movember Translation Acceleration Grants 2016
October 25, 2016 - Prostate Cancer Canada is pleased to announce the successful candidates from the Translation Acceleration Grants 2016 competition. Grants are meant to address a significant issue in the management of prostate cancer, with a high potential of preventing disease progression and/or improving quality of life in the short term. The grants should leverage existing knowledge and have the capability to accelerate impact. The emphasis of this funding opportunity is to develop an intervention that can be studied in a patient or population study within a 5-year timeframe.
This opportunity is proudly funded by the Movember Foundation and represents a total investment of $4,477,177 over three years commencing April 1, 2016.
| Principal Investigator |
Institution |
Title |
Funded Amount |
| Bernhard Eigl |
BC Cancer Agency
Vancouver, BC |
The PRIME Study - PRevention and Intervention for MEtabolic syndrome |
$1,498,452 |
| Martin Gleave |
University of British Columbia
Vancouver, BC |
Computer-aided design of novel inhibitors of Hsp27 |
$1,480,000 |
| Laurence Klotz |
Canadian Urology Research Consortium
Toronto, ON |
A randomised controlled trial of magnetic resonance imaging-targeted biopsy compared to standard trans-rectal ultrasound guided biopsy for the diagnosis of prostate cancer in men without prior biopsy |
$1,498,725 |
Special Project in Non-Metastatic Castrate Resistant Prostate Cancer 2016
April 5, 2016 – Prostate Cancer Canada is pleased to announce the successful candidate from the Special Project in Non-Metastatic Castrate Resistant Prostate Cancer (NM-CRPC) competition. This award solicits proposals from groups interested in combining various real world data sources (i.e. detailed chart review at prostate cancer centres with health administrative databases) to obtain high quality epidemiological data, outcomes and costs among the population of prostate cancer patients in at least two provinces in Canada that together represent greater than 50% of the population.
The key objectives of this program are:
- to obtain prevalence, incidence and survival probability estimates of prostate cancer, stratified by age and year of diagnosis from provincial cancer registries;
- to identify pathways leading to and factors associated with the target condition (NM-CRPC);
- to estimate annual incidence and prevalence of NM-CRPC, stratified probability of developing NM-CRPC and transition probabilities that characterize the prognosis from NM-CRPC to metastasis and end-of-life;
- to estimate health care resource use and costs for health states in the recurrent disease model.
This opportunity represents a total investment of $425,437 over two years commencing April 1, 2016.
Principal
Investigator |
Institution |
Title |
Funded Amount |
| Murray Krahn |
University Health Network
Toronto, ON |
Non-metastatic castrate resistant prostate cancer: epidemiology, clinical pathways, and health care costs |
$425,437 |
Movember Rising Stars in Prostate Cancer Research 2016
December 16, 2015 – Prostate Cancer Canada is pleased to announce the successful candidates from the Rising Stars in Prostate Cancer Research competition. These awards provide salary and research support for outstanding researchers within the first 5 years of their first academic or research appointment to develop and demonstrate independence in a career in prostate cancer research.
This opportunity, proudly funded by the Movember Foundation, represents a total investment of $1,345,199. Each award is for three years, commencing January 1, 2016, to a maximum of $450,000.
|
Principal
Investigator
|
Institution |
Title |
Funded Amount |
| Housheng He |
University Health Network
Toronto, ON |
Epigenetic mechanisms underlying prostate cancer development and progression |
$445,200 |
| Hon Leong |
Lawson Health Research Institute
London, ON |
Antagonizing molecular mechanisms responsible for cancer cell extravasation to combat prostate cancer metastasis |
$450,000 |
| Alexander Wyatt |
University of British Columbia
Vancouver, BC |
Detecting druggable DNA repair defects in advanced prostate cancer |
$449,999 |
Movember Team Grant 2015
June 10, 2015 - Prostate Cancer Canada and Movember are proud to announce the recipient of the 2015 Movember Team Grant. Team grant funding supports integrated, multi-disciplinary research programs involving high-quality independent investigators who share knowledge and resources while working towards a unifying overall scientific goal. The successful team must propose a well-defined program of research that encompasses several aspects of prostate cancer research that are clearly interrelated and synergistic so that efforts and outcomes have more impact than if funded as separate grants. The program must have participating principal investigators from a minimum of three institutions and provide a formal training program.
An international panel of reviewers was assembled to adjudicate the team grants competition. The applications were submitted to a multi-stage and layered review process; narrowing the field to a short list of applicant teams invited to a reverse site visit in Toronto.
This represents a total investment of $4,995,400 over five years starting July 1, 2015.
| Program Director and Principal Investigator |
Institution |
Title |
Funded Amount |
| John Bell |
Ottawa Hospital Research Institute
Ottawa, ON |
Development of a targeted oncolytic virus vaccine for the treatment of metastatic prostate cancer |
$4,990,498 |
| Team Members: |
Institutions: |
Jean-Simon Diallo
Co-Principal Investigator |
Ottawa Hospital Research Institute
Ottawa, ON |
Sébastien Hotte
Co-Principal Investigator |
McMaster University
Hamilton, ON |
Brian Lichty
Co-Principal Investigator |
McMaster University
Hamilton, ON |
Fred Saad
Co-Principal Investigator |
Centre Hospitalier de l'Université de Montréal
Montreal, QC |
Eric Belanger
Co-Investigator |
Ottawa Hospital
Ottawa, ON |
Jonathan Bramson
Co-Investigator |
McMaster University
Hamilton, ON |
Rodney Breau
Co-Investigator |
Ottawa Hospital Research Institute
Ottawa, ON |
Dean Fergusson
Co-Investigator |
Ottawa Hospital Research Institute
Ottawa, ON |
Derek Jonker
Co-Investigator |
University of Ottawa
Ottawa, ON |
Andrea McCart
Co-Investigator |
University of Toronto
Toronto, ON |
David Stojdl
Co-Investigator |
Children's Hospital of Eastern Ontario
Ottawa, ON |
Yonghong Wan
Co-Investigator |
McMaster University
Hamilton, ON |
Movember True NTH Survivorship Research Grants 2015
March 27, 2015 - Prostate Cancer Canada (PCC) and Movember are proud to announce the results of the Movember Targeted RFA in Survivorship Research competition. Projects aim to inform the development and delivery of interventions and best practices in follow-up care for cancer patients, survivors and their families and caregivers.
Three grants have been funded starting April 1, 2015, representing a total investment of $2,065,895 over the next three to five years.
| Principal Investigator |
Institution |
Title |
Funded Amount |
| Shabbir Alibhai |
University Health Network
Toronto, ON |
Toward personalizing care for older men with mCRPC - Princess Margaret Cancer Centre, University Health Network and predicting treatment toxicities
(the TOPCOP study) |
$413,830 |
| Jennifer Jones |
University Health Network
Toronto, ON |
Prostate Cancer Survivorship 360° |
$1,281,025 |
| Sylvie Lambert |
McGill University
Montreal, QC |
Reducing anxiety and enhancing quality of life among caregivers of prostate cancer survivors: Development and evaluation of a dyadic, tailored, web-based, psychosocial and physical activity self-management programme |
$434,040 |
Movember Clinical Trial in Prostate Cancer 2015
March 20, 2015 - Prostate Cancer Canada (PCC) and Movember are proud to announce the results of the Movember Clinical Trials in Prostate Cancer competition. Applications were accepted for investigator-initiated clinical trials studying the iatrogenic effects of prostate cancer treatment with an overall aim of mitigating effects that are unintended and unwanted.
One grant has been funded starting April 1, 2015, representing a total investment of $3,449,136 over a five-year term.
| Principal Investigator |
Institution |
Title |
Funded Amount |
| Jehonathan Pinthus |
McMaster University
Hamilton, ON |
Role of androgen deprivation therapy in cardiovascular disease - a longitudinal prostate cancer study (RADICAL PC) |
$3,449,136 |